What test is done after a positive Rapid Plasma Reagin (RPR) test for syphilis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Confirmatory Testing After Positive RPR for Syphilis

After a positive Rapid Plasma Reagin (RPR) test for syphilis, a treponemal-specific test such as TP-PA (Treponema pallidum particle agglutination) or FTA-ABS (fluorescent treponemal antibody absorption) should be performed as confirmatory testing. 1

Understanding Syphilis Testing Algorithms

There are two main testing approaches for syphilis:

  1. Traditional Algorithm:

    • Starts with a nontreponemal test (RPR or VDRL)
    • Positive results are confirmed with a treponemal-specific test
  2. Reverse Sequence Algorithm:

    • Starts with a treponemal test
    • Positive results are followed by a nontreponemal test

When an RPR is positive, confirmatory testing is essential because nontreponemal tests can yield false-positive results in various conditions.

Recommended Confirmatory Tests

The CDC and clinical guidelines recommend the following treponemal tests for confirmation 1:

  • TP-PA (Treponema pallidum particle agglutination) - Preferred option due to:

    • High sensitivity (95-100%)
    • Excellent specificity (100%)
    • Superior sensitivity compared to FTA-ABS, especially in primary syphilis
  • Other acceptable options:

    • FTA-ABS (fluorescent treponemal antibody absorption)
    • EIA (enzyme immunoassay)
    • CIA (chemiluminescence immunoassay)

Test Performance Characteristics

Test Sensitivity Specificity Notes
RPR/VDRL 50-92.7% 95-100% Nontreponemal tests
TP-PA 95-100% 100% Preferred confirmatory test
FTA-ABS 78.2-95% 95-100% Less sensitive for primary syphilis
EIA/CIA 94.5-100% 95-100% Newer automated methods

Important Considerations

  • False-positive RPR results are more common in:

    • Women (0.27% vs 0.20% in men)
    • Patients over 60 years (0.34% vs 0.25% in younger patients) 1
  • Test selection matters: FTA-ABS has poor sensitivity (78.2%) for primary syphilis compared to other treponemal tests (94.5-96.4%) 2

  • Discordant results: When treponemal tests are reactive but nontreponemal tests are nonreactive, additional treponemal testing may be needed to rule out false positives 1

After Confirmation: Treatment and Monitoring

If syphilis is confirmed:

  1. Treatment should be initiated based on disease stage:

    • Primary/secondary: Benzathine penicillin G 2.4 million units IM as a single dose
    • Late latent/unknown duration: Benzathine penicillin G 2.4 million units IM once weekly for 3 weeks
  2. Monitoring should include:

    • Quantitative nontreponemal testing at 3,6,9, and 12 months
    • Expected fourfold decline in titers within 6 months for primary/secondary syphilis
    • Failure to decline may indicate treatment failure or reinfection 1

Clinical Pitfalls to Avoid

  • Don't rely solely on nontreponemal tests for diagnosis due to potential false positives
  • Don't use FTA-ABS as first-line confirmatory test due to inferior sensitivity in primary syphilis
  • Don't confuse treatment failure with reinfection - a fourfold increase after initial decline may indicate reinfection rather than failure
  • Don't forget partner notification and treatment - essential for preventing reinfection and further transmission

Remember that treponemal tests typically remain positive for life even after successful treatment, while nontreponemal tests are used to monitor treatment response.

References

Guideline

Syphilis Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Performance of Treponemal Tests for the Diagnosis of Syphilis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.